Comparing Fresh Tracks Therapeutics (NASDAQ:FRTX) & Kyverna Therapeutics (NASDAQ:KYTX)

Fresh Tracks Therapeutics (NASDAQ:FRTX) and Kyverna Therapeutics (NASDAQ:KYTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, earnings, dividends and profitability.

Analyst Ratings

This is a summary of current ratings and recommmendations for Fresh Tracks Therapeutics and Kyverna Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fresh Tracks Therapeutics	0	0	0	0	0.00
Kyverna Therapeutics	0	1	5	1	3.00

Kyverna Therapeutics has a consensus price target of $18.33, indicating a potential upside of 707.64%. Given Kyverna Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Kyverna Therapeutics is more favorable than Fresh Tracks Therapeutics.

Risk and Volatility

Fresh Tracks Therapeutics has a beta of 0.54, suggesting that its stock price is 46% less volatile than the S&P 500. Comparatively, Kyverna Therapeutics has a beta of 2.17, suggesting that its stock price is 117% more volatile than the S&P 500.

Insider and Institutional Ownership

25.0% of Fresh Tracks Therapeutics shares are owned by institutional investors. Comparatively, 18.1% of Kyverna Therapeutics shares are owned by institutional investors. 0.2% of Fresh Tracks Therapeutics shares are owned by insiders. Comparatively, 22.0% of Kyverna Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Fresh Tracks Therapeutics and Kyverna Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fresh Tracks Therapeutics	$10.06 million	0.56	-$5.69 million	($1.41)	-0.66
Kyverna Therapeutics	$7.03 million	13.96	-$60.37 million	($3.38)	-0.67

Fresh Tracks Therapeutics has higher revenue and earnings than Kyverna Therapeutics. Kyverna Therapeutics is trading at a lower price-to-earnings ratio than Fresh Tracks Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Fresh Tracks Therapeutics and Kyverna Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Fresh Tracks Therapeutics	N/A	N/A	N/A
Kyverna Therapeutics	N/A	-51.12%	-37.91%

About Fresh Tracks Therapeutics

Fresh Tracks Therapeutics, Inc. does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.

About Kyverna Therapeutics

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.